OTCMKTS:AGYTF Allergy Therapeutics (AGYTF) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free AGYTF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range N/A52-Week Range$0.17▼$0.19VolumeN/AAverage VolumeN/AMarket Capitalization$13.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesShort InterestStock AnalysisHeadlinesShort Interest Get Allergy Therapeutics alerts: Email Address Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. About Allergy Therapeutics Stock (OTCMKTS:AGYTF)Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.Read More Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. AGYTF Stock News HeadlinesApril 26, 2024 | msn.comLSU Gymnastics National Championship parade, celebrationApril 25, 2024 | msn.comTHRUSDAY AT 6 ON KATU NEWS| Nightly fuel thefts plague U-HAUL rental locationsApril 27, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 25, 2024 | msn.comWATCH LIVE TONIGHT AT 6 P.M. : LSU Gymnastics National Championship parade, celebrationApril 24, 2024 | finance.yahoo.comOPERATION HOPE CEO JOHN HOPE BRYANT'S LATEST BOOK, 'FINANCIAL LITERACY FOR ALL,' DEBUTS AT #12 ON USA TODAY BESTSELLER LISTApril 17, 2024 | finance.yahoo.comFREE CHICKEN SALAD FOR MOMS THIS MOTHER'S DAY AT CHICKEN SALAD CHICKApril 16, 2024 | finance.yahoo.comLIGHTING THE WAY FORWARD AT "THE CRADLE OF HUMANKIND" IN DESTINATION: SCIENTOLOGY, JOHANNESBURGApril 16, 2024 | msn.comTONIGHT AT 6: An incredible update on Vicky, the disabled woman living on the side of I-5April 27, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 9, 2024 | finance.yahoo.comGACA: GLOBAL AVIATION LEADERS TO ADDRESS AVIATION CHALLENGES AND OPPORTUNITIES AT 2024 FUTURE AVIATION FORUM IN RIYADH, MAY 20-22April 8, 2024 | msn.comLEGO's AT-AT set gets price cut in time-limited dealMarch 26, 2024 | finance.yahoo.comHAPPY HOPPY HOLIDAY AT GALAXY MACAU WITH EGGS-TRA SPECIAL EASTER MENUSMarch 20, 2024 | msn.comNokian Outpost AT long-term wrap-up: Decent tires, snow or noMarch 19, 2024 | finance.yahoo.comREDCON1 ENERGY LAUNCHES AT CIRCLE K STORESMarch 15, 2024 | msn.comMONDAY AT 6: KATU exclusive report reveals plead deal trends in Mult. Co. murder casesMarch 13, 2024 | msn.comTOMORROW AT 6| KATU will hold a town hall on the future of Portland's fentanyl crisisMarch 12, 2024 | msn.comAllergy Therapeutics doses patients in second part of peanut allergy trialMarch 12, 2024 | finance.yahoo.comYALO RISES HIGH AT THE HORIZON AWARDS WITH MULTIPLE WINSMarch 12, 2024 | lse.co.ukAllergy Therapeutics starts dosing patients in peanut allergy trialMarch 8, 2024 | msn.comSOME REPUBLICANS THINK BIDEN DID TOO MUCH YELLING AT SOTUFebruary 29, 2024 | finance.yahoo.comWebinar: AT&S introduces the future of computingFebruary 27, 2024 | finance.yahoo.comJESSICA EGERTON, A SEASONED MARKETING EXECUTIVE WITH TWO DECADES OF BUILDING BRANDS, NAMED VICE PRESIDENT OF MARKETING AT KUMHO TIRE U.S.A.February 23, 2024 | msn.comAT LAST! Urban Boarding Experience plans big expansionFebruary 22, 2024 | markets.businessinsider.comIntrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy TreatmentFebruary 21, 2024 | msn.comLEGO's AT-AT set gets a big price cutFebruary 20, 2024 | msn.comYokohama launches Geolandar X-AT and M/T G003 tyres in IndiaFebruary 19, 2024 | msn.comAT THE PLATE: See Jacksonville high school softball top teams, players to watch in 2024See More Headlines Receive AGYTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:AGYTF Previous SymbolNASDAQ:AGYTF CUSIPN/A CIKN/A Webwww.allergytherapeutics.com Phone44-19-0384-4700FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$73.41 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-2.00Miscellaneous Outstanding Shares688,950,000Free FloatN/AMarket Cap$13.78 million OptionableNot Optionable Beta516.99 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Manuel Llobet (Age 57)CEO & Exec. Director Comp: $683.78kMr. Nicolas Alexander Ulrich Wykeman (Age 56)CFO & Exec. Director Comp: $392.3kMs. Beverly LeesGroup Operations DirectorDr. Murray SkinnerChief Scientific OfficerMr. Santiago PuigBus. Devel. DirectorMs. Sue BakerHead of HRSimon PiggottHead of Clinical ScienceAlan BullimoreHead of Communication & Market Devel.Mr. Russell PicketGroup Financial ControllerSara GoldsbroughCompany Sec.More ExecutivesKey CompetitorsPreveCeutical MedicalOTCMKTS:PRVCFPoxelOTCMKTS:PXXLFNicoxOTCMKTS:NICXFMDxHealthOTCMKTS:MXDHFElse NutritionOTCMKTS:BABYFView All Competitors This page (OTCMKTS:AGYTF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
